Afuco™ Anti-Human IL13 ADCC Therapeutic Antibody (RPC4046), ADCC Enhanced
Anti-IL13 ADCC Enhanced Antibody (RPC4046) is an ADCC enhanced antibody produced by our Afuco™ platform. RPC4046 is a monoclonal antibody currently being studied in a Phase 2 trial for the treatment of eosinophilic esophagitis (EoE). RPC4046 is directed against the interleukin-13 (IL-13) target, which has been validated in other allergy-related disorders including asthma. The development program for RPC4046 builds upon competencies in immunology and GI diseases.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-379CL |
| Pricing | Inquiry |
| Host | Humanized |
| Target | IL13 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | Store at -20°C for long-term storage. Store at 4°C for up to one month. Avoid freeze/thaw cycles. |